Reconsidering antiviral prophylaxis in HBsAg-negative, anti–HBc-positive patients treated with rituximab

George Papatheodoridis, Jessica Hwang

Open source

DOI
10.1097/hc9.0000000000000903
Published
2026-02-26
Container
Hepatology Communications
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/hc9.0000000000000903,
  title = {Reconsidering antiviral prophylaxis in HBsAg-negative, anti–HBc-positive patients treated with rituximab},
  author = {George Papatheodoridis and Jessica Hwang},
  year = {2026},
  journal = {Hepatology Communications},
  doi = {10.1097/hc9.0000000000000903},
  url = {https://doi.org/10.1097/hc9.0000000000000903}
}

RIS

TY  - JOUR
TI  - Reconsidering antiviral prophylaxis in HBsAg-negative, anti–HBc-positive patients treated with rituximab
AU  - George Papatheodoridis
AU  - Jessica Hwang
PY  - 2026
JO  - Hepatology Communications
DO  - 10.1097/hc9.0000000000000903
UR  - https://doi.org/10.1097/hc9.0000000000000903
ER  - 

APA

Papatheodoridis, G., & Hwang, J. (2026). Reconsidering antiviral prophylaxis in HBsAg-negative, anti–HBc-positive patients treated with rituximab. Hepatology Communications. https://doi.org/10.1097/hc9.0000000000000903

Source records